1 Report Overview 1.1 Study Scope 1.2 Market Analysis by Type 1.2.1 Global Non-oncology Biopharmaceuticals Market Size Growth Rate by Type: 2019 VS 2023 VS 2030 1.2.2 Biologics 1.2.3 Biosimilars 1.3 Market by Application 1.3.1 Global Non-oncology Biopharmaceuticals Market Growth by Application: 2019 VS 2023 VS 2030 1.3.2 Immunology 1.3.3 Endocrinology 1.3.4 Others 1.4 Study Objectives 1.5 Years Considered 1.6 Years Considered 2 Global Growth Trends 2.1 Global Non-oncology Biopharmaceuticals Market Perspective (2019-2030) 2.2 Non-oncology Biopharmaceuticals Growth Trends by Region 2.2.1 Global Non-oncology Biopharmaceuticals Market Size by Region: 2019 VS 2023 VS 2030 2.2.2 Non-oncology Biopharmaceuticals Historic Market Size by Region (2019-2024) 2.2.3 Non-oncology Biopharmaceuticals Forecasted Market Size by Region (2025-2030) 2.3 Non-oncology Biopharmaceuticals Market Dynamics 2.3.1 Non-oncology Biopharmaceuticals Industry Trends 2.3.2 Non-oncology Biopharmaceuticals Market Drivers 2.3.3 Non-oncology Biopharmaceuticals Market Challenges 2.3.4 Non-oncology Biopharmaceuticals Market Restraints 3 Competition Landscape by Key Players 3.1 Global Top Non-oncology Biopharmaceuticals Players by Revenue 3.1.1 Global Top Non-oncology Biopharmaceuticals Players by Revenue (2019-2024) 3.1.2 Global Non-oncology Biopharmaceuticals Revenue Market Share by Players (2019-2024) 3.2 Global Non-oncology Biopharmaceuticals Market Share by Company Type (Tier 1, Tier 2, and Tier 3) 3.3 Players Covered: Ranking by Non-oncology Biopharmaceuticals Revenue 3.4 Global Non-oncology Biopharmaceuticals Market Concentration Ratio 3.4.1 Global Non-oncology Biopharmaceuticals Market Concentration Ratio (CR5 and HHI) 3.4.2 Global Top 10 and Top 5 Companies by Non-oncology Biopharmaceuticals Revenue in 2023 3.5 Non-oncology Biopharmaceuticals Key Players Head office and Area Served 3.6 Key Players Non-oncology Biopharmaceuticals Product Solution and Service 3.7 Date of Enter into Non-oncology Biopharmaceuticals Market 3.8 Mergers & Acquisitions, Expansion Plans 4 Non-oncology Biopharmaceuticals Breakdown Data by Type 4.1 Global Non-oncology Biopharmaceuticals Historic Market Size by Type (2019-2024) 4.2 Global Non-oncology Biopharmaceuticals Forecasted Market Size by Type (2025-2030) 5 Non-oncology Biopharmaceuticals Breakdown Data by Application 5.1 Global Non-oncology Biopharmaceuticals Historic Market Size by Application (2019-2024) 5.2 Global Non-oncology Biopharmaceuticals Forecasted Market Size by Application (2025-2030) 6 North America 6.1 North America Non-oncology Biopharmaceuticals Market Size (2019-2030) 6.2 North America Non-oncology Biopharmaceuticals Market Growth Rate by Country: 2019 VS 2023 VS 2030 6.3 North America Non-oncology Biopharmaceuticals Market Size by Country (2019-2024) 6.4 North America Non-oncology Biopharmaceuticals Market Size by Country (2025-2030) 6.5 United States 6.6 Canada 7 Europe 7.1 Europe Non-oncology Biopharmaceuticals Market Size (2019-2030) 7.2 Europe Non-oncology Biopharmaceuticals Market Growth Rate by Country: 2019 VS 2023 VS 2030 7.3 Europe Non-oncology Biopharmaceuticals Market Size by Country (2019-2024) 7.4 Europe Non-oncology Biopharmaceuticals Market Size by Country (2025-2030) 7.5 Germany 7.6 France 7.7 U.K. 7.8 Italy 7.9 Russia 7.10 Nordic Countries 8 Asia-Pacific 8.1 Asia-Pacific Non-oncology Biopharmaceuticals Market Size (2019-2030) 8.2 Asia-Pacific Non-oncology Biopharmaceuticals Market Growth Rate by Region: 2019 VS 2023 VS 2030 8.3 Asia-Pacific Non-oncology Biopharmaceuticals Market Size by Region (2019-2024) 8.4 Asia-Pacific Non-oncology Biopharmaceuticals Market Size by Region (2025-2030) 8.5 China 8.6 Japan 8.7 South Korea 8.8 Southeast Asia 8.9 India 8.10 Australia 9 Latin America 9.1 Latin America Non-oncology Biopharmaceuticals Market Size (2019-2030) 9.2 Latin America Non-oncology Biopharmaceuticals Market Growth Rate by Country: 2019 VS 2023 VS 2030 9.3 Latin America Non-oncology Biopharmaceuticals Market Size by Country (2019-2024) 9.4 Latin America Non-oncology Biopharmaceuticals Market Size by Country (2025-2030) 9.5 Mexico 9.6 Brazil 10 Middle East & Africa 10.1 Middle East & Africa Non-oncology Biopharmaceuticals Market Size (2019-2030) 10.2 Middle East & Africa Non-oncology Biopharmaceuticals Market Growth Rate by Country: 2019 VS 2023 VS 2030 10.3 Middle East & Africa Non-oncology Biopharmaceuticals Market Size by Country (2019-2024) 10.4 Middle East & Africa Non-oncology Biopharmaceuticals Market Size by Country (2025-2030) 10.5 Turkey 10.6 Saudi Arabia 10.7 UAE 11 Key Players Profiles 11.1 Roche 11.1.1 Roche Company Detail 11.1.2 Roche Business Overview 11.1.3 Roche Non-oncology Biopharmaceuticals Introduction 11.1.4 Roche Revenue in Non-oncology Biopharmaceuticals Business (2019-2024) 11.1.5 Roche Recent Development 11.2 Sanofi 11.2.1 Sanofi Company Detail 11.2.2 Sanofi Business Overview 11.2.3 Sanofi Non-oncology Biopharmaceuticals Introduction 11.2.4 Sanofi Revenue in Non-oncology Biopharmaceuticals Business (2019-2024) 11.2.5 Sanofi Recent Development 11.3 Johnson & Johnson 11.3.1 Johnson & Johnson Company Detail 11.3.2 Johnson & Johnson Business Overview 11.3.3 Johnson & Johnson Non-oncology Biopharmaceuticals Introduction 11.3.4 Johnson & Johnson Revenue in Non-oncology Biopharmaceuticals Business (2019-2024) 11.3.5 Johnson & Johnson Recent Development 11.4 Pfizer 11.4.1 Pfizer Company Detail 11.4.2 Pfizer Business Overview 11.4.3 Pfizer Non-oncology Biopharmaceuticals Introduction 11.4.4 Pfizer Revenue in Non-oncology Biopharmaceuticals Business (2019-2024) 11.4.5 Pfizer Recent Development 11.5 Novo Nordisk 11.5.1 Novo Nordisk Company Detail 11.5.2 Novo Nordisk Business Overview 11.5.3 Novo Nordisk Non-oncology Biopharmaceuticals Introduction 11.5.4 Novo Nordisk Revenue in Non-oncology Biopharmaceuticals Business (2019-2024) 11.5.5 Novo Nordisk Recent Development 11.6 Novartis 11.6.1 Novartis Company Detail 11.6.2 Novartis Business Overview 11.6.3 Novartis Non-oncology Biopharmaceuticals Introduction 11.6.4 Novartis Revenue in Non-oncology Biopharmaceuticals Business (2019-2024) 11.6.5 Novartis Recent Development 11.7 Merck 11.7.1 Merck Company Detail 11.7.2 Merck Business Overview 11.7.3 Merck Non-oncology Biopharmaceuticals Introduction 11.7.4 Merck Revenue in Non-oncology Biopharmaceuticals Business (2019-2024) 11.7.5 Merck Recent Development 11.8 Teva 11.8.1 Teva Company Detail 11.8.2 Teva Business Overview 11.8.3 Teva Non-oncology Biopharmaceuticals Introduction 11.8.4 Teva Revenue in Non-oncology Biopharmaceuticals Business (2019-2024) 11.8.5 Teva Recent Development 11.9 Eli Lilly 11.9.1 Eli Lilly Company Detail 11.9.2 Eli Lilly Business Overview 11.9.3 Eli Lilly Non-oncology Biopharmaceuticals Introduction 11.9.4 Eli Lilly Revenue in Non-oncology Biopharmaceuticals Business (2019-2024) 11.9.5 Eli Lilly Recent Development 11.10 Bristol-Myers Squibb 11.10.1 Bristol-Myers Squibb Company Detail 11.10.2 Bristol-Myers Squibb Business Overview 11.10.3 Bristol-Myers Squibb Non-oncology Biopharmaceuticals Introduction 11.10.4 Bristol-Myers Squibb Revenue in Non-oncology Biopharmaceuticals Business (2019-2024) 11.10.5 Bristol-Myers Squibb Recent Development 11.11 GlaxoSmithKline 11.11.1 GlaxoSmithKline Company Detail 11.11.2 GlaxoSmithKline Business Overview 11.11.3 GlaxoSmithKline Non-oncology Biopharmaceuticals Introduction 11.11.4 GlaxoSmithKline Revenue in Non-oncology Biopharmaceuticals Business (2019-2024) 11.11.5 GlaxoSmithKline Recent Development 11.12 UCB Pharma 11.12.1 UCB Pharma Company Detail 11.12.2 UCB Pharma Business Overview 11.12.3 UCB Pharma Non-oncology Biopharmaceuticals Introduction 11.12.4 UCB Pharma Revenue in Non-oncology Biopharmaceuticals Business (2019-2024) 11.12.5 UCB Pharma Recent Development 11.13 Amgen 11.13.1 Amgen Company Detail 11.13.2 Amgen Business Overview 11.13.3 Amgen Non-oncology Biopharmaceuticals Introduction 11.13.4 Amgen Revenue in Non-oncology Biopharmaceuticals Business (2019-2024) 11.13.5 Amgen Recent Development 11.14 AbbVie 11.14.1 AbbVie Company Detail 11.14.2 AbbVie Business Overview 11.14.3 AbbVie Non-oncology Biopharmaceuticals Introduction 11.14.4 AbbVie Revenue in Non-oncology Biopharmaceuticals Business (2019-2024) 11.14.5 AbbVie Recent Development 11.15 Takeda 11.15.1 Takeda Company Detail 11.15.2 Takeda Business Overview 11.15.3 Takeda Non-oncology Biopharmaceuticals Introduction 11.15.4 Takeda Revenue in Non-oncology Biopharmaceuticals Business (2019-2024) 11.15.5 Takeda Recent Development 11.16 AstraZeneca 11.16.1 AstraZeneca Company Detail 11.16.2 AstraZeneca Business Overview 11.16.3 AstraZeneca Non-oncology Biopharmaceuticals Introduction 11.16.4 AstraZeneca Revenue in Non-oncology Biopharmaceuticals Business (2019-2024) 11.16.5 AstraZeneca Recent Development 11.17 Mylan 11.17.1 Mylan Company Detail 11.17.2 Mylan Business Overview 11.17.3 Mylan Non-oncology Biopharmaceuticals Introduction 11.17.4 Mylan Revenue in Non-oncology Biopharmaceuticals Business (2019-2024) 11.17.5 Mylan Recent Development 11.18 LEO Pharma 11.18.1 LEO Pharma Company Detail 11.18.2 LEO Pharma Business Overview 11.18.3 LEO Pharma Non-oncology Biopharmaceuticals Introduction 11.18.4 LEO Pharma Revenue in Non-oncology Biopharmaceuticals Business (2019-2024) 11.18.5 LEO Pharma Recent Development 11.19 Boehringer Ingelheim 11.19.1 Boehringer Ingelheim Company Detail 11.19.2 Boehringer Ingelheim Business Overview 11.19.3 Boehringer Ingelheim Non-oncology Biopharmaceuticals Introduction 11.19.4 Boehringer Ingelheim Revenue in Non-oncology Biopharmaceuticals Business (2019-2024) 11.19.5 Boehringer Ingelheim Recent Development 11.20 Alexion Pharmaceuticals 11.20.1 Alexion Pharmaceuticals Company Detail 11.20.2 Alexion Pharmaceuticals Business Overview 11.20.3 Alexion Pharmaceuticals Non-oncology Biopharmaceuticals Introduction 11.20.4 Alexion Pharmaceuticals Revenue in Non-oncology Biopharmaceuticals Business (2019-2024) 11.20.5 Alexion Pharmaceuticals Recent Development 11.21 Elusys Therapeutics 11.21.1 Elusys Therapeutics Company Detail 11.21.2 Elusys Therapeutics Business Overview 11.21.3 Elusys Therapeutics Non-oncology Biopharmaceuticals Introduction 11.21.4 Elusys Therapeutics Revenue in Non-oncology Biopharmaceuticals Business (2019-2024) 11.21.5 Elusys Therapeutics Recent Development 11.22 Swedish Orphan Biovitrum 11.22.1 Swedish Orphan Biovitrum Company Detail 11.22.2 Swedish Orphan Biovitrum Business Overview 11.22.3 Swedish Orphan Biovitrum Non-oncology Biopharmaceuticals Introduction 11.22.4 Swedish Orphan Biovitrum Revenue in Non-oncology Biopharmaceuticals Business (2019-2024) 11.22.5 Swedish Orphan Biovitrum Recent Development 11.23 Biogen 11.23.1 Biogen Company Detail 11.23.2 Biogen Business Overview 11.23.3 Biogen Non-oncology Biopharmaceuticals Introduction 11.23.4 Biogen Revenue in Non-oncology Biopharmaceuticals Business (2019-2024) 11.23.5 Biogen Recent Development 12 Analyst's Viewpoints/Conclusions 13 Appendix 13.1 Research Methodology 13.1.1 Methodology/Research Approach 13.1.2 Data Source 13.2 Disclaimer 13.3 Author Details

List of Tables Table 1. Global Non-oncology Biopharmaceuticals Market Size Growth Rate by Type (US$ Million): 2019 VS 2023 VS 2030 Table 2. Key Players of Biologics Table 3. Key Players of Biosimilars Table 4. Global Non-oncology Biopharmaceuticals Market Size Growth by Application (US$ Million): 2019 VS 2023 VS 2030 Table 5. Global Non-oncology Biopharmaceuticals Market Size by Region (US$ Million): 2019 VS 2023 VS 2030 Table 6. Global Non-oncology Biopharmaceuticals Market Size by Region (2019-2024) & (US$ Million) Table 7. Global Non-oncology Biopharmaceuticals Market Share by Region (2019-2024) Table 8. Global Non-oncology Biopharmaceuticals Forecasted Market Size by Region (2025-2030) & (US$ Million) Table 9. Global Non-oncology Biopharmaceuticals Market Share by Region (2025-2030) Table 10. Non-oncology Biopharmaceuticals Market Trends Table 11. Non-oncology Biopharmaceuticals Market Drivers Table 12. Non-oncology Biopharmaceuticals Market Challenges Table 13. Non-oncology Biopharmaceuticals Market Restraints Table 14. Global Non-oncology Biopharmaceuticals Revenue by Players (2019-2024) & (US$ Million) Table 15. Global Non-oncology Biopharmaceuticals Market Share by Players (2019-2024) Table 16. Global Top Non-oncology Biopharmaceuticals Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Non-oncology Biopharmaceuticals as of 2023) Table 17. Ranking of Global Top Non-oncology Biopharmaceuticals Companies by Revenue (US$ Million) in 2023 Table 18. Global 5 Largest Players Market Share by Non-oncology Biopharmaceuticals Revenue (CR5 and HHI) & (2019-2024) Table 19. Key Players Headquarters and Area Served Table 20. Key Players Non-oncology Biopharmaceuticals Product Solution and Service Table 21. Date of Enter into Non-oncology Biopharmaceuticals Market Table 22. Mergers & Acquisitions, Expansion Plans Table 23. Global Non-oncology Biopharmaceuticals Market Size by Type (2019-2024) & (US$ Million) Table 24. Global Non-oncology Biopharmaceuticals Revenue Market Share by Type (2019-2024) Table 25. Global Non-oncology Biopharmaceuticals Forecasted Market Size by Type (2025-2030) & (US$ Million) Table 26. Global Non-oncology Biopharmaceuticals Revenue Market Share by Type (2025-2030) Table 27. Global Non-oncology Biopharmaceuticals Market Size by Application (2019-2024) & (US$ Million) Table 28. Global Non-oncology Biopharmaceuticals Revenue Market Share by Application (2019-2024) Table 29. Global Non-oncology Biopharmaceuticals Forecasted Market Size by Application (2025-2030) & (US$ Million) Table 30. Global Non-oncology Biopharmaceuticals Revenue Market Share by Application (2025-2030) Table 31. North America Non-oncology Biopharmaceuticals Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030 Table 32. North America Non-oncology Biopharmaceuticals Market Size by Country (2019-2024) & (US$ Million) Table 33. North America Non-oncology Biopharmaceuticals Market Size by Country (2025-2030) & (US$ Million) Table 34. Europe Non-oncology Biopharmaceuticals Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030 Table 35. Europe Non-oncology Biopharmaceuticals Market Size by Country (2019-2024) & (US$ Million) Table 36. Europe Non-oncology Biopharmaceuticals Market Size by Country (2025-2030) & (US$ Million) Table 37. Asia-Pacific Non-oncology Biopharmaceuticals Market Size Growth Rate by Region (US$ Million): 2019 VS 2023 VS 2030 Table 38. Asia-Pacific Non-oncology Biopharmaceuticals Market Size by Region (2019-2024) & (US$ Million) Table 39. Asia-Pacific Non-oncology Biopharmaceuticals Market Size by Region (2025-2030) & (US$ Million) Table 40. Latin America Non-oncology Biopharmaceuticals Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030 Table 41. Latin America Non-oncology Biopharmaceuticals Market Size by Country (2019-2024) & (US$ Million) Table 42. Latin America Non-oncology Biopharmaceuticals Market Size by Country (2025-2030) & (US$ Million) Table 43. Middle East & Africa Non-oncology Biopharmaceuticals Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030 Table 44. Middle East & Africa Non-oncology Biopharmaceuticals Market Size by Country (2019-2024) & (US$ Million) Table 45. Middle East & Africa Non-oncology Biopharmaceuticals Market Size by Country (2025-2030) & (US$ Million) Table 46. Roche Company Detail Table 47. Roche Business Overview Table 48. Roche Non-oncology Biopharmaceuticals Product Table 49. Roche Revenue in Non-oncology Biopharmaceuticals Business (2019-2024) & (US$ Million) Table 50. Roche Recent Development Table 51. Sanofi Company Detail Table 52. Sanofi Business Overview Table 53. Sanofi Non-oncology Biopharmaceuticals Product Table 54. Sanofi Revenue in Non-oncology Biopharmaceuticals Business (2019-2024) & (US$ Million) Table 55. Sanofi Recent Development Table 56. Johnson & Johnson Company Detail Table 57. Johnson & Johnson Business Overview Table 58. Johnson & Johnson Non-oncology Biopharmaceuticals Product Table 59. Johnson & Johnson Revenue in Non-oncology Biopharmaceuticals Business (2019-2024) & (US$ Million) Table 60. Johnson & Johnson Recent Development Table 61. Pfizer Company Detail Table 62. Pfizer Business Overview Table 63. Pfizer Non-oncology Biopharmaceuticals Product Table 64. Pfizer Revenue in Non-oncology Biopharmaceuticals Business (2019-2024) & (US$ Million) Table 65. Pfizer Recent Development Table 66. Novo Nordisk Company Detail Table 67. Novo Nordisk Business Overview Table 68. Novo Nordisk Non-oncology Biopharmaceuticals Product Table 69. Novo Nordisk Revenue in Non-oncology Biopharmaceuticals Business (2019-2024) & (US$ Million) Table 70. Novo Nordisk Recent Development Table 71. Novartis Company Detail Table 72. Novartis Business Overview Table 73. Novartis Non-oncology Biopharmaceuticals Product Table 74. Novartis Revenue in Non-oncology Biopharmaceuticals Business (2019-2024) & (US$ Million) Table 75. Novartis Recent Development Table 76. Merck Company Detail Table 77. Merck Business Overview Table 78. Merck Non-oncology Biopharmaceuticals Product Table 79. Merck Revenue in Non-oncology Biopharmaceuticals Business (2019-2024) & (US$ Million) Table 80. Merck Recent Development Table 81. Teva Company Detail Table 82. Teva Business Overview Table 83. Teva Non-oncology Biopharmaceuticals Product Table 84. Teva Revenue in Non-oncology Biopharmaceuticals Business (2019-2024) & (US$ Million) Table 85. Teva Recent Development Table 86. Eli Lilly Company Detail Table 87. Eli Lilly Business Overview Table 88. Eli Lilly Non-oncology Biopharmaceuticals Product Table 89. Eli Lilly Revenue in Non-oncology Biopharmaceuticals Business (2019-2024) & (US$ Million) Table 90. Eli Lilly Recent Development Table 91. Bristol-Myers Squibb Company Detail Table 92. Bristol-Myers Squibb Business Overview Table 93. Bristol-Myers Squibb Non-oncology Biopharmaceuticals Product Table 94. Bristol-Myers Squibb Revenue in Non-oncology Biopharmaceuticals Business (2019-2024) & (US$ Million) Table 95. Bristol-Myers Squibb Recent Development Table 96. GlaxoSmithKline Company Detail Table 97. GlaxoSmithKline Business Overview Table 98. GlaxoSmithKline Non-oncology Biopharmaceuticals Product Table 99. GlaxoSmithKline Revenue in Non-oncology Biopharmaceuticals Business (2019-2024) & (US$ Million) Table 100. GlaxoSmithKline Recent Development Table 101. UCB Pharma Company Detail Table 102. UCB Pharma Business Overview Table 103. UCB Pharma Non-oncology Biopharmaceuticals Product Table 104. UCB Pharma Revenue in Non-oncology Biopharmaceuticals Business (2019-2024) & (US$ Million) Table 105. UCB Pharma Recent Development Table 106. Amgen Company Detail Table 107. Amgen Business Overview Table 108. Amgen Non-oncology Biopharmaceuticals Product Table 109. Amgen Revenue in Non-oncology Biopharmaceuticals Business (2019-2024) & (US$ Million) Table 110. Amgen Recent Development Table 111. AbbVie Company Detail Table 112. AbbVie Business Overview Table 113. AbbVie Non-oncology Biopharmaceuticals Product Table 114. AbbVie Revenue in Non-oncology Biopharmaceuticals Business (2019-2024) & (US$ Million) Table 115. AbbVie Recent Development Table 116. Takeda Company Detail Table 117. Takeda Business Overview Table 118. Takeda Non-oncology Biopharmaceuticals Product Table 119. Takeda Revenue in Non-oncology Biopharmaceuticals Business (2019-2024) & (US$ Million) Table 120. Takeda Recent Development Table 121. AstraZeneca Company Detail Table 122. AstraZeneca Business Overview Table 123. AstraZeneca Non-oncology Biopharmaceuticals Product Table 124. AstraZeneca Revenue in Non-oncology Biopharmaceuticals Business (2019-2024) & (US$ Million) Table 125. AstraZeneca Recent Development Table 126. Mylan Company Detail Table 127. Mylan Business Overview Table 128. Mylan Non-oncology Biopharmaceuticals Product Table 129. Mylan Revenue in Non-oncology Biopharmaceuticals Business (2019-2024) & (US$ Million) Table 130. Mylan Recent Development Table 131. LEO Pharma Company Detail Table 132. LEO Pharma Business Overview Table 133. LEO Pharma Non-oncology Biopharmaceuticals Product Table 134. LEO Pharma Revenue in Non-oncology Biopharmaceuticals Business (2019-2024) & (US$ Million) Table 135. LEO Pharma Recent Development Table 136. Boehringer Ingelheim Company Detail Table 137. Boehringer Ingelheim Business Overview Table 138. Boehringer Ingelheim Non-oncology Biopharmaceuticals Product Table 139. Boehringer Ingelheim Revenue in Non-oncology Biopharmaceuticals Business (2019-2024) & (US$ Million) Table 140. Boehringer Ingelheim Recent Development Table 141. Alexion Pharmaceuticals Company Detail Table 142. Alexion Pharmaceuticals Business Overview Table 143. Alexion Pharmaceuticals Non-oncology Biopharmaceuticals Product Table 144. Alexion Pharmaceuticals Revenue in Non-oncology Biopharmaceuticals Business (2019-2024) & (US$ Million) Table 145. Alexion Pharmaceuticals Recent Development Table 146. Elusys Therapeutics Company Detail Table 147. Elusys Therapeutics Business Overview Table 148. Elusys Therapeutics Non-oncology Biopharmaceuticals Product Table 149. Elusys Therapeutics Revenue in Non-oncology Biopharmaceuticals Business (2019-2024) & (US$ Million) Table 150. Elusys Therapeutics Recent Development Table 151. Swedish Orphan Biovitrum Company Detail Table 152. Swedish Orphan Biovitrum Business Overview Table 153. Swedish Orphan Biovitrum Non-oncology Biopharmaceuticals Product Table 154. Swedish Orphan Biovitrum Revenue in Non-oncology Biopharmaceuticals Business (2019-2024) & (US$ Million) Table 155. Swedish Orphan Biovitrum Recent Development Table 156. Biogen Company Detail Table 157. Biogen Business Overview Table 158. Biogen Non-oncology Biopharmaceuticals Product Table 159. Biogen Revenue in Non-oncology Biopharmaceuticals Business (2019-2024) & (US$ Million) Table 160. Biogen Recent Development Table 161. Research Programs/Design for This Report Table 162. Key Data Information from Secondary Sources Table 163. Key Data Information from Primary Sources List of Figures Figure 1. Global Non-oncology Biopharmaceuticals Market Size Comparison by Type (2024-2030) & (US$ Million) Figure 2. Global Non-oncology Biopharmaceuticals Market Share by Type: 2023 VS 2030 Figure 3. Biologics Features Figure 4. Biosimilars Features Figure 5. Global Non-oncology Biopharmaceuticals Market Size Comparison by Application (2024-2030) & (US$ Million) Figure 6. Global Non-oncology Biopharmaceuticals Market Share by Application: 2023 VS 2030 Figure 7. Immunology Case Studies Figure 8. Endocrinology Case Studies Figure 9. Others Case Studies Figure 10. Non-oncology Biopharmaceuticals Report Years Considered Figure 11. Global Non-oncology Biopharmaceuticals Market Size (US$ Million), Year-over-Year: 2019-2030 Figure 12. Global Non-oncology Biopharmaceuticals Market Size, (US$ Million), 2019 VS 2023 VS 2030 Figure 13. Global Non-oncology Biopharmaceuticals Market Share by Region: 2023 VS 2030 Figure 14. Global Non-oncology Biopharmaceuticals Market Share by Players in 2023 Figure 15. Global Top Non-oncology Biopharmaceuticals Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Non-oncology Biopharmaceuticals as of 2023) Figure 16. The Top 10 and 5 Players Market Share by Non-oncology Biopharmaceuticals Revenue in 2023 Figure 17. North America Non-oncology Biopharmaceuticals Market Size YoY Growth (2019-2030) & (US$ Million) Figure 18. North America Non-oncology Biopharmaceuticals Market Share by Country (2019-2030) Figure 19. United States Non-oncology Biopharmaceuticals Market Size YoY Growth (2019-2030) & (US$ Million) Figure 20. Canada Non-oncology Biopharmaceuticals Market Size YoY Growth (2019-2030) & (US$ Million) Figure 21. Europe Non-oncology Biopharmaceuticals Market Size YoY Growth (2019-2030) & (US$ Million) Figure 22. Europe Non-oncology Biopharmaceuticals Market Share by Country (2019-2030) Figure 23. Germany Non-oncology Biopharmaceuticals Market Size YoY Growth (2019-2030) & (US$ Million) Figure 24. France Non-oncology Biopharmaceuticals Market Size YoY Growth (2019-2030) & (US$ Million) Figure 25. U.K. Non-oncology Biopharmaceuticals Market Size YoY Growth (2019-2030) & (US$ Million) Figure 26. Italy Non-oncology Biopharmaceuticals Market Size YoY Growth (2019-2030) & (US$ Million) Figure 27. Russia Non-oncology Biopharmaceuticals Market Size YoY Growth (2019-2030) & (US$ Million) Figure 28. Nordic Countries Non-oncology Biopharmaceuticals Market Size YoY Growth (2019-2030) & (US$ Million) Figure 29. Asia-Pacific Non-oncology Biopharmaceuticals Market Size YoY Growth (2019-2030) & (US$ Million) Figure 30. Asia-Pacific Non-oncology Biopharmaceuticals Market Share by Region (2019-2030) Figure 31. China Non-oncology Biopharmaceuticals Market Size YoY Growth (2019-2030) & (US$ Million) Figure 32. Japan Non-oncology Biopharmaceuticals Market Size YoY Growth (2019-2030) & (US$ Million) Figure 33. South Korea Non-oncology Biopharmaceuticals Market Size YoY Growth (2019-2030) & (US$ Million) Figure 34. Southeast Asia Non-oncology Biopharmaceuticals Market Size YoY Growth (2019-2030) & (US$ Million) Figure 35. India Non-oncology Biopharmaceuticals Market Size YoY Growth (2019-2030) & (US$ Million) Figure 36. Australia Non-oncology Biopharmaceuticals Market Size YoY Growth (2019-2030) & (US$ Million) Figure 37. Latin America Non-oncology Biopharmaceuticals Market Size YoY Growth (2019-2030) & (US$ Million) Figure 38. Latin America Non-oncology Biopharmaceuticals Market Share by Country (2019-2030) Figure 39. Mexico Non-oncology Biopharmaceuticals Market Size YoY Growth (2019-2030) & (US$ Million) Figure 40. Brazil Non-oncology Biopharmaceuticals Market Size YoY Growth (2019-2030) & (US$ Million) Figure 41. Middle East & Africa Non-oncology Biopharmaceuticals Market Size YoY Growth (2019-2030) & (US$ Million) Figure 42. Middle East & Africa Non-oncology Biopharmaceuticals Market Share by Country (2019-2030) Figure 43. Turkey Non-oncology Biopharmaceuticals Market Size YoY Growth (2019-2030) & (US$ Million) Figure 44. Saudi Arabia Non-oncology Biopharmaceuticals Market Size YoY Growth (2019-2030) & (US$ Million) Figure 45. Roche Revenue Growth Rate in Non-oncology Biopharmaceuticals Business (2019-2024) Figure 46. Sanofi Revenue Growth Rate in Non-oncology Biopharmaceuticals Business (2019-2024) Figure 47. Johnson & Johnson Revenue Growth Rate in Non-oncology Biopharmaceuticals Business (2019-2024) Figure 48. Pfizer Revenue Growth Rate in Non-oncology Biopharmaceuticals Business (2019-2024) Figure 49. Novo Nordisk Revenue Growth Rate in Non-oncology Biopharmaceuticals Business (2019-2024) Figure 50. Novartis Revenue Growth Rate in Non-oncology Biopharmaceuticals Business (2019-2024) Figure 51. Merck Revenue Growth Rate in Non-oncology Biopharmaceuticals Business (2019-2024) Figure 52. Teva Revenue Growth Rate in Non-oncology Biopharmaceuticals Business (2019-2024) Figure 53. Eli Lilly Revenue Growth Rate in Non-oncology Biopharmaceuticals Business (2019-2024) Figure 54. Bristol-Myers Squibb Revenue Growth Rate in Non-oncology Biopharmaceuticals Business (2019-2024) Figure 55. GlaxoSmithKline Revenue Growth Rate in Non-oncology Biopharmaceuticals Business (2019-2024) Figure 56. UCB Pharma Revenue Growth Rate in Non-oncology Biopharmaceuticals Business (2019-2024) Figure 57. Amgen Revenue Growth Rate in Non-oncology Biopharmaceuticals Business (2019-2024) Figure 58. AbbVie Revenue Growth Rate in Non-oncology Biopharmaceuticals Business (2019-2024) Figure 59. Takeda Revenue Growth Rate in Non-oncology Biopharmaceuticals Business (2019-2024) Figure 60. AstraZeneca Revenue Growth Rate in Non-oncology Biopharmaceuticals Business (2019-2024) Figure 61. Mylan Revenue Growth Rate in Non-oncology Biopharmaceuticals Business (2019-2024) Figure 62. LEO Pharma Revenue Growth Rate in Non-oncology Biopharmaceuticals Business (2019-2024) Figure 63. Boehringer Ingelheim Revenue Growth Rate in Non-oncology Biopharmaceuticals Business (2019-2024) Figure 64. Alexion Pharmaceuticals Revenue Growth Rate in Non-oncology Biopharmaceuticals Business (2019-2024) Figure 65. Elusys Therapeutics Revenue Growth Rate in Non-oncology Biopharmaceuticals Business (2019-2024) Figure 66. Swedish Orphan Biovitrum Revenue Growth Rate in Non-oncology Biopharmaceuticals Business (2019-2024) Figure 67. Biogen Revenue Growth Rate in Non-oncology Biopharmaceuticals Business (2019-2024) Figure 68. Bottom-up and Top-down Approaches for This Report Figure 69. Data Triangulation Figure 70. Key Executives Interviewed